<DOC>
	<DOCNO>NCT00075777</DOCNO>
	<brief_summary>RATIONALE : Valproic acid may help stop growth Kaposi 's sarcoma cell block enzymes necessary tumor cell growth . PURPOSE : This clinical trial study valproic acid treat patient HIV-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Valproic Acid Treating Patients With Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety valproic acid patient Kaposi 's sarcoma . - Determine effect drug human herpes virus 8 ( KSHV ) gene expression use polymerase chain reaction immunohistochemistry patient . Secondary - Determine effect drug HIV , KSHV , Epstein-Barr virus viral load plasma peripheral blood mononuclear cell patient . - Determine clinical response patient treated drug . OUTLINE : This open-label , pilot , multicenter study . Patients receive oral valproic acid twice daily day 1-28 followed drug taper 2 week . Treatment continue absence disease progression unacceptable toxicity . Patients follow monthly 6 month . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm HIVrelated Kaposi 's sarcoma ( KS ) Disease involve skin and/or lymph nod No symptomatic visceral disease No oral KS site disease Slowly progressive stable disease allow Slow progression define few 5 new lesion per month Must document HIV infection positive ELISA , western Blot , viral load determination CD4 Tcell count &gt; 50/mm^3 PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) * AST ALT ≤ 3 time ULN Albumin &gt; 2.5 g/dL NOTE : *Elevated total bilirubin ( ≤ 3.5 mg/dL ) secondary indinavir therapy allow provide direct bilirubin normal Renal Creatinine &lt; 1.5 time ULN Cardiovascular No prior myocardial infarction No evidence cardiac ischemia Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No prior lactic acidosis &gt; 2.0 mmoles/L No prior lipoatrophy hypercholesterolemia secondary retroviral treatment No concurrent , acute , active opportunistic infection oral thrush genital herpes within past 14 day No concurrent neoplasm require cytotoxic therapy PRIOR CONCURRENT THERAPY : Biologic therapy More 2 week since prior biologic therapy KS Chemotherapy More 2 week since prior chemotherapy KS No concurrent systemic cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy More 2 week since prior radiotherapy KS Surgery Not specify Other More 2 week since prior antineoplastic local therapy KS More 2 week since prior investigational therapy KS More 60 day since prior local therapy KSmarker lesion unless lesion clearly progress since therapy More 1 year since prior valproic acid Concurrent antiretroviral therapy allow provided regimen stable least 4 week No concurrent zidovudine No concurrent KSspecific therapy No concurrent investigational drug , INDapproved antiretroviral agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>recurrent Kaposi sarcoma</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
</DOC>